Human Brain Transcriptomics: Towards Understanding Multiple System Atrophy
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Highland Park Public Schools Highland Park, New Jersey Mission Statement
HIGHLAND PARK PUBLIC SCHOOLS HIGHLAND PARK, NEW JERSEY MISSION STATEMENT The mission of the Highland Park School District is to provide the community with the finest educational services through respect for diversity and commitment to collaboration, continuous improvement, and achievement of excellence. The Highland Park Board of Education will hold a REGULAR PUBLIC MEETING on Monday, September 19, 2016, at 6:30 p.m., at the Middle School, 330 Wayne Street, Highland Park, New Jersey. This meeting will be broadcast live on hpschools.net and youtube.com. AGENDA: 1. Call to Order 2. Announcement of Notice The New Jersey Open Public Meetings Act was enacted to ensure the right of the public to have advance notice of and to attend the meetings of the public bodies at which any business affecting their interest is discussed or acted upon. In compliance with the Open Public Meeting Act, the Highland Park Board of Education has caused notice of this meeting setting forth the time, date, and location to be submitted for publication to the Home News Tribune and Star Ledger and posted on the Board’s website at least 48 hours in advance of this meeting. Members of the public who wish to address the Board will be given the opportunity to do so before the Board adjourns for the evening. 3. Roll Call 4. Recess to Executive Session Be It Resolved, pursuant to the Sunshine Act, N.J.S.A. 10:4-12 and 13, the Highland Park Board of Education will now meet in closed session to discuss litigation. This exemption is permitted to be discussed in closed session in accordance with N.J.S.A. -
2019 OPSSD York University for Publication 03022020.Xlsx
Record of employees' 2019 salaries and benefits Registre des traitements et avantages verses aux employes en 2019 Taxable Salary Paid / Cal Year / Employer / Benefits / Sector / Secteur Surname / Nom de famille Given Name / Prenom Position Title / Poste Traitement Avantages Annee Civil Employeur verse imposable 2019 Universities York University Abbruzzese Teresa V.A. Sessional Assistant Professor 104,007.36 573.20 2019 Universities York University Abdel-Shehid Gamal Associate Professor 171,018.74 899.84 2019 Universities York University Abdul Sater Ali Assistant Professor 125,484.66 677.36 2019 Universities York University Abdullah Thabit A J Professor 177,570.47 960.16 2019 Universities York University Ablack Christine Manager, Job Evaluation and Compensation Services 122,465.13 668.04 2019 Universities York University Aboelaze Mokhtar Associate Professor 210,094.66 1,094.64 2019 Universities York University Abouchar Chantal Team Lecturer 105,597.56 0.00 2019 Universities York University Adam Simon Assistant Professor 115,475.96 636.88 2019 Universities York University Adamopoulos Anastasios T Associate Professor 180,491.49 979.00 2019 Universities York University Adegoke Olasunkanmi A J Associate Professor 156,871.90 849.00 2019 Universities York University Adler Daniel A Associate Professor 139,569.20 815.84 2019 Universities York University Adler Scott A. Associate Professor 160,020.20 865.52 2019 Universities York University Adriaen Monique Associate Professor 188,563.18 341.24 2019 Universities York University Agathangelou Anna -
Comparison of Orthologs Across Multiple Species by Various Strategies
COMPARISON OF ORTHOLOGS ACROSS MULTIPLE SPECIES BY VARIOUS STRATEGIES BY HUI LIU DISSERTATION Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biophysics and Computational Biology in the Graduate College of the University of Illinois at Urbana-Champaign, 2014 Urbana, Illinois Doctoral Committee: Professor Eric Jakobsson, Chair, Director of Research Professor Gene E. Robinson Associate Professor Saurabh Sinha Assistant Professor Jian Ma Abstract Thanks to the improvement of genome sequencing technology, abundant multi-species genomic data now became available and comparative genomics continues to be a fast prospering filed of biological research. Through the comparison of genomes of different organisms, we can understand what, at the molecular level, distinguishes different life forms from each other. It shed light on revealing the evolution of biology. And it also helps to refine the annotations and functions of individual genomes. For example, through comparisons across mammalian genomes, we can give an estimate of the conserved set of genes across mammals and correspondingly, find the species-specific sets of genes or functions. However, comparative genomics can be feasible only if a meaningful classification of genes exists. A natural way to do so is to delineate sets of orthologous genes. However, debates exist about the appropriate way to define orthologs. It is originally defined as genes in different species which derive from speciation events. But such definition is not sufficient to derive orthologous genes due to the complexity of evolutionary events such as gene duplication and gene loss. While it is possible to correctly figure out all the evolutionary events with the true phylogenetic tree, the true phylogenetic tree itself is impractical to be inferred. -
Celecoxib Treatment Alters the Gene Expression Profile of Normal Colonic Mucosa
1382 Celecoxib Treatment Alters the Gene Expression Profile of Normal Colonic Mucosa Oleg K. Glebov,1 Luz M. Rodriguez,1 Patrick Lynch,4 Sherri Patterson,4 Henry Lynch,5 Kenneth Nakahara,1 Jean Jenkins,1 Janet Cliatt,1 Casey-Jo Humbyrd,1 John DeNobile,3 Peter Soballe,3 Steven Gallinger,6 Aby Buchbinder,7 Gary Gordon,8 Ernest Hawk,2 and Ilan R. Kirsch1 1Genetics Branch, Center for Cancer Research; 2Division of Cancer Prevention, National Cancer Institute; 3Surgery Department, National Naval Medical Center, Bethesda, Maryland; 4University of Texas M.D. Anderson Cancer Center, Houston, Texas; 5Creighton University, Omaha, Nebraska; 6University of Toronto, Toronto, Ontario, Canada; 7Pharmacia, Peapack, New Jersey; and 8Ovation Pharma, Lincolnshire, Illinois Abstract A clinical trial was recently conducted to evaluate the safety Twenty-three of 25 pairs of colon biopsies taken before and efficacy of a selective inhibitor of cyclooxygenase-2 and after celecoxib treatment can be classified correctly (celecoxib) in hereditary nonpolyposis colon cancer by the pattern of gene expression in a leave-one-out patients. In a randomized, placebo-controlled phase I/II cross-validation. Immune response, particularly T- and B- multicenter trial, hereditary nonpolyposis colon cancer lymphocyte activation and early steps of inflammatory patients and gene carriers received either celecoxib at one reaction, cell signaling and cell adhesion, response to stress, of two doses or placebo. The goal was to evaluate the effects transforming growth factor-B signaling, and regulation of of these treatment arms on a number of endoscopic and apoptosis, are the main biological processes targeted by tissue-based biomarker end points after 12 months of celecoxib as shown by overrepresentation analysis of the treatment. -
El Ferro I Els Ferrers En L'antroponímia Catalana I Europea Trobam Com a Nom De Família Ferrer O Algun Equivalent
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Biblioteca Digital de les Illes Balears EL FERRO I ELS FERRERS EN L’ANTROPONÍMIA CATALANA I EUROPEA Antoni Llull Martí XIX Jornada d’Antroponímia i Toponímia. Muro, 2006 Des que fa prop de tres mil cinc-cents anys, els hitites descobriren la manera de forjar el ferro i utilitzar-lo per fer-ne armes, eines i molts diversos utensilis, crec que podem donar per segur que aquest metall és el que més ha contribuït, i contribueix encara, al desenvo- lupament de la civilització. En els segles següents a aquest descobriment, els pobles que desenvoluparen les tècniques per obrar el ferro tingueren grans avantatges sobre els que les desconeixien, i encara durant l’edat mitjana, l’ofici de ferrer era molt preuat i, per això, quan per devers el segle XII començaren a fer-se usuals als països cristians de l’entorn del Mediterrani occidental els llinatges hereditaris, molts dels qui tenien aqueix ofici adoptaren Ferrer com a nom de família. Un vell nom personal germànic introduït a Catalunya pels visigots i que s’ha conservat al nostre país com a llinatge, és Isern, que en documents catalans dels segles X i XI, escrits en llatí com era usual en aquella època, es troba escrit Isarn i Isarnus, derivat, segons sem- bla, del mateix mot germànic del que procedeix l’alemany modern Eisen ‘ferro’, documen- tat en antic alt alemany amb les formes isarn i isan, i en gòtic eisarn.1 Altres antics noms germànics composts amb aquest mateix mot i un altre que els complementa, són Isanbard, Isanbald, Isenburg, Isenfrid, Isimbert, que han estat molt poc, o no gens, usuals en la nostra antroponímia medieval, i molt menys en la moderna. -
Supplementary Data
Supplementary Fig. 1 A B Responder_Xenograft_ Responder_Xenograft_ NON- NON- Lu7336, Vehicle vs Lu7466, Vehicle vs Responder_Xenograft_ Responder_Xenograft_ Sagopilone, Welch- Sagopilone, Welch- Lu7187, Vehicle vs Lu7406, Vehicle vs Test: 638 Test: 600 Sagopilone, Welch- Sagopilone, Welch- Test: 468 Test: 482 Responder_Xenograft_ NON- Lu7860, Vehicle vs Responder_Xenograft_ Sagopilone, Welch - Lu7558, Vehicle vs Test: 605 Sagopilone, Welch- Test: 333 Supplementary Fig. 2 Supplementary Fig. 3 Supplementary Figure S1. Venn diagrams comparing probe sets regulated by Sagopilone treatment (10mg/kg for 24h) between individual models (Welsh Test ellipse p-value<0.001 or 5-fold change). A Sagopilone responder models, B Sagopilone non-responder models. Supplementary Figure S2. Pathway analysis of genes regulated by Sagopilone treatment in responder xenograft models 24h after Sagopilone treatment by GeneGo Metacore; the most significant pathway map representing cell cycle/spindle assembly and chromosome separation is shown, genes upregulated by Sagopilone treatment are marked with red thermometers. Supplementary Figure S3. GeneGo Metacore pathway analysis of genes differentially expressed between Sagopilone Responder and Non-Responder models displaying –log(p-Values) of most significant pathway maps. Supplementary Tables Supplementary Table 1. Response and activity in 22 non-small-cell lung cancer (NSCLC) xenograft models after treatment with Sagopilone and other cytotoxic agents commonly used in the management of NSCLC Tumor Model Response type -
Urzędu Patentowego
BIULETYN URZĘDU PATENTOWEGO Wydawnictwo Urzędu Patentowego Polskiej Rzeczypospolitej Ludowej 4 (136) Warszawa 1979 Urząd Patentowy PRL - na podstawie art. 33 1 art. 78 ustawy z dnia 18 października 1972 r. o wynalaz- czości (Dz. U. PRL Nr 43, poz. 272) - dokonuje ogłoszenia w „Biuletynie Urzędu Patentowego" o zgłoszo- nych wynalazkach i wzorach użytkowych. Ogłoszenia o zgłoszeniach drukowane w „Biuletynie" podane są w układzie klasowym według symboli Int. CL« i zgodnie z § 26 ust. 4 zarządzenia Prezesa Urzędu Patento- wego PRL z dnia 21 XII 1972 r. w sprawie ochrony wynalazków i wzorów użytkowych (MP z 1973 r. nr 1 poz. 4) zawierają następujące dane: - oznaczenie klasy i podklasy według symboli II edycji międzynarodowej klasyfikacji patentowej, tj. Int. CL1 - numer zgłoszenia wynalazku lub wzoru użytkowego, - datę zgłoszenia wynalazku lub wzoru użytkowego, - datę i kraj uprzedniego pierwszeństwa oraz numer zgłoszenia dokonanego za granicą lub oznaczenie wy- stawy - jeżeli zastrzeżono pierwszeństwo, - imię i nazwisko lub nazwę zgłaszającego, - miejsce zamieszkania lub siedzibę oraz kraj zgłaszającego, - imię i nazwisko wynalazcy (wynalazców), - tytuł wynalazku lub wzoru użytkowego, - skrót opisu wynalazku lub wzoru użytkowego wraz z figurą rysunku najlepiej obrazującą wynalazek lub wzór użytkowy, - liczbę zastrzeżeń. Po wykazie ogłoszeń w układzie klasowym według symboli Int. Cl.f podaje się wykaz zgłoszeń opubliko- wanych w danym numerze w układzie numerowym. Ogłoszenia dotyczące zgłoszeń o udzielenie patentów tymczasowych zostały oznaczone -
Record of Employees' 2020 Salaries and Benefits Registre Des Traitements Et Avantages Verses Aux Employes En 2020
Record of employees' 2020 salaries and benefits Registre des traitements et avantages verses aux employes en 2020 Taxable Calendar Salary Paid Sector Last Name First Name Position Title Organization Benefits Year Traitement Secteur Nom de famille Prénom Poste Organisation Avantages Année Civil verse imposable 2020 Universities Abbruzzese Teresa V.A. Assistant Professor Teaching York University 119,434.92 577.23 2020 Universities Abdel-Shehid Gamal Associate Professor York University 177,761.42 895.52 2020 Universities Abdul Sater Ali Assistant Professor York University 128,168.92 678.12 2020 Universities Abdullah Thabit A J Professor York University 177,778.58 940.22 2020 Universities Abdullah Shamim Course Director York University 113,914.24 - 2020 Universities Ablack Christine Manager Job Evaluation and Compensation Services York University 129,479.63 446.13 2020 Universities Aboelaze Mokhtar Associate Professor York University 206,764.44 1,057.56 2020 Universities Abouchar Chantal Course Director York University 114,914.18 - 2020 Universities Abou-Hanna Mireille Director Recruitment Admissions and Applicant Relations York University 106,002.25 551.77 2020 Universities Abu Sabaa Sally Manager English for Academic Purposes York University 104,161.96 541.59 2020 Universities Adam Simon Assistant Professor York University 120,688.28 639.36 2020 Universities Adamopoulos Anastasios T Associate Professor York University 183,927.20 973.72 2020 Universities Adegoke Olasunkanmi A J Associate Professor York University 159,874.36 846.20 2020 Universities -
Nº Ref Uniprot Proteína Péptidos Identificados Por MS/MS 1 P01024
Document downloaded from http://www.elsevier.es, day 26/09/2021. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited. Nº Ref Uniprot Proteína Péptidos identificados 1 P01024 CO3_HUMAN Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 por 162MS/MS 2 P02751 FINC_HUMAN Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=4 131 3 P01023 A2MG_HUMAN Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 128 4 P0C0L4 CO4A_HUMAN Complement C4-A OS=Homo sapiens GN=C4A PE=1 SV=1 95 5 P04275 VWF_HUMAN von Willebrand factor OS=Homo sapiens GN=VWF PE=1 SV=4 81 6 P02675 FIBB_HUMAN Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1 SV=2 78 7 P01031 CO5_HUMAN Complement C5 OS=Homo sapiens GN=C5 PE=1 SV=4 66 8 P02768 ALBU_HUMAN Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 66 9 P00450 CERU_HUMAN Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 64 10 P02671 FIBA_HUMAN Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2 58 11 P08603 CFAH_HUMAN Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 56 12 P02787 TRFE_HUMAN Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 54 13 P00747 PLMN_HUMAN Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2 48 14 P02679 FIBG_HUMAN Fibrinogen gamma chain OS=Homo sapiens GN=FGG PE=1 SV=3 47 15 P01871 IGHM_HUMAN Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3 41 16 P04003 C4BPA_HUMAN C4b-binding protein alpha chain OS=Homo sapiens GN=C4BPA PE=1 SV=2 37 17 Q9Y6R7 FCGBP_HUMAN IgGFc-binding protein OS=Homo sapiens GN=FCGBP PE=1 SV=3 30 18 O43866 CD5L_HUMAN CD5 antigen-like OS=Homo -
Target Gene Gene Description Validation Diana Miranda
Supplemental Table S1. Mmu-miR-183-5p in silico predicted targets. TARGET GENE GENE DESCRIPTION VALIDATION DIANA MIRANDA MIRBRIDGE PICTAR PITA RNA22 TARGETSCAN TOTAL_HIT AP3M1 adaptor-related protein complex 3, mu 1 subunit V V V V V V V 7 BTG1 B-cell translocation gene 1, anti-proliferative V V V V V V V 7 CLCN3 chloride channel, voltage-sensitive 3 V V V V V V V 7 CTDSPL CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-like V V V V V V V 7 DUSP10 dual specificity phosphatase 10 V V V V V V V 7 MAP3K4 mitogen-activated protein kinase kinase kinase 4 V V V V V V V 7 PDCD4 programmed cell death 4 (neoplastic transformation inhibitor) V V V V V V V 7 PPP2R5C protein phosphatase 2, regulatory subunit B', gamma V V V V V V V 7 PTPN4 protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte) V V V V V V V 7 EZR ezrin V V V V V V 6 FOXO1 forkhead box O1 V V V V V V 6 ANKRD13C ankyrin repeat domain 13C V V V V V V 6 ARHGAP6 Rho GTPase activating protein 6 V V V V V V 6 BACH2 BTB and CNC homology 1, basic leucine zipper transcription factor 2 V V V V V V 6 BNIP3L BCL2/adenovirus E1B 19kDa interacting protein 3-like V V V V V V 6 BRMS1L breast cancer metastasis-suppressor 1-like V V V V V V 6 CDK5R1 cyclin-dependent kinase 5, regulatory subunit 1 (p35) V V V V V V 6 CTDSP1 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase 1 V V V V V V 6 DCX doublecortin V V V V V V 6 ENAH enabled homolog (Drosophila) V V V V V V 6 EPHA4 EPH receptor A4 V V V V V V 6 FOXP1 forkhead box P1 V -
2019 SSG Rowing Participation List
Florida Sports Foundation Sunshine State Games Participant Listing 2019 SSG Rowing Participation List # First Name Last Name Hometown City State 1 Jorge Acosta Miami FL 2 Dragos Alexandru Osprey FL 3 Mario Alonso Miami FL 4 Raul Arellano Miami FL 5 Vladimir Banjanac Serbia SRB 6 Sarah Barlow Orlando FL 7 Facundo Barrera Miami FL 8 Robert Bauer Gainesville FL 9 Mary Benedict Gainesville FL 10 Britton Bertram Orlando FL 11 Rebecca Bolletti Osprey FL 12 Debbie Brazill Inverness FL 13 David Brizzi 14 Victoria Brooks Orlando FL 15 Julie Brown Osprey FL 16 Jonathan Campana Osprey FL 17 John Carter Osprey FL 18 Yamile Castella Miami FL 19 julian chauhan Osprey FL 20 Larry Chlebina Osprey FL 21 Tyler Cirillo Orlando FL 22 Matthew Coble Tampa FL 23 Lindsey Collins Orlando FL 24 Liam Collins Osprey FL 25 Maureen Condiotte Osprey FL 26 Laura Corbett Osprey FL 27 Tamara Currey Osprey FL 28 Don Davis Gainesville FL 29 Amanda Davis Orlando FL 30 Kerri Davis Osprey FL 31 Joao Eduardo de Sousa 32 Jesus Devesa Orlando FL 33 Constance Dodds Osprey FL 34 MaryEl Duncan Gainesville FL 35 Morgan Earp Osprey FL 36 Thomas Edwards Osprey FL 37 Carl Eierle Plantation FL 38 Jon Einsidler Osprey FL Quarterly DEO Report: June 30, 2019 Page 1 of 5 Florida Sports Foundation Sunshine State Games Participant Listing 2019 SSG Rowing Participation List # First Name Last Name Hometown City State 39 John Eisnor Osprey FL 40 Lisa Elkins Orlando FL 41 Leslie Evans Osprey FL 42 Jennifer Figueroa Gainesville FL 43 John Fischer Osprey FL 44 Matthew Freeburg Osprey FL 45 Frank -
Candidate Genes for Alcohol Preference Identified by Expression
Liang et al. Genome Biology 2010, 11:R11 http://genomebiology.com/2010/11/2/R11 RESEARCH Open Access Candidate genes for alcohol preference identified by expression profiling in alcohol-preferring and -nonpreferring reciprocal congenic rats Tiebing Liang1*, Mark W Kimpel2, Jeanette N McClintick3, Ashley R Skillman1, Kevin McCall4, Howard J Edenberg3, Lucinda G Carr1 Abstract Background: Selectively bred alcohol-preferring (P) and alcohol-nonpreferring (NP) rats differ greatly in alcohol preference, in part due to a highly significant quantitative trait locus (QTL) on chromosome 4. Alcohol consumption scores of reciprocal chromosome 4 congenic strains NP.P and P.NP correlated with the introgressed interval. The goal of this study was to identify candidate genes that may influence alcohol consumption by comparing gene expression in five brain regions of alcohol-naïve inbred alcohol-preferring and P.NP congenic rats: amygdala, nucleus accumbens, hippocampus, caudate putamen, and frontal cortex. Results: Within the QTL region, 104 cis-regulated probe sets were differentially expressed in more than one region, and an additional 53 were differentially expressed in a single region. Fewer trans-regulated probe sets were detected, and most differed in only one region. Analysis of the average expression values across the 5 brain regions yielded 141 differentially expressed cis-regulated probe sets and 206 trans-regulated probe sets. Comparing the present results from inbred alcohol-preferring vs. congenic P.NP rats to earlier results from the reciprocal congenic NP.P vs. inbred alcohol-nonpreferring rats demonstrated that 74 cis-regulated probe sets were differentially expressed in the same direction and with a consistent magnitude of difference in at least one brain region.